Flucloxacillin Dosing for MSSA Pneumonia
For severe MSSA pneumonia in adults with normal renal function, administer flucloxacillin 2 g IV every 4-6 hours (8-12 g/day), preferably by continuous infusion at 8-12 g/24 hours to optimize pharmacodynamic target attainment.
Severe Infection Dosing (Normal Renal Function)
The evidence strongly supports high-dose regimens for severe MSSA infections:
- Standard severe infection dose: 2 g IV every 4-6 hours (8-12 g/day total)
- Preferred delivery method: Continuous infusion of 8-12 g/24 hours
The rationale for continuous infusion stems from flucloxacillin's time-dependent killing profile. Beta-lactam efficacy against MSSA correlates with the time serum concentrations exceed the MIC (fT>MIC), not peak concentrations 1. Research demonstrates that continuous infusion of 8-12 g/day maintains serum concentrations of 8->40 mg/L, well above typical MSSA MICs, and achieved 82% cure rates in serious staphylococcal infections 1.
Critical consideration for critically ill patients: Standard dosing frequently results in underdosing. In critically ill patients with hypoalbuminaemia, unbound flucloxacillin concentrations after 2 g bolus fell below 1 mg/L within 4 hours, insufficient for MSSA with MIC = 2 mg/L 2. Monte Carlo simulations indicate that continuous infusion of 8 g/24 hours achieves 100% target attainment for 50% fT>MIC, but more aggressive targets (4-5x MIC for 100% fT>MIC) require 12 g/24 hours 2. A 2023 multicenter study found only 26% target attainment with 12 g continuous infusion and 51% with 24 g, suggesting even higher doses may be needed in some critically ill patients 3.
Less Severe Infection Dosing
For non-severe MSSA infections (not pneumonia):
- Standard dose: 1-2 g IV every 6 hours (4-8 g/day)
- Mild-moderate infections: 500 mg - 1 g IV every 6 hours
The lower end of this range is appropriate for uncomplicated skin/soft tissue infections, while pneumonia—even when less severe—warrants higher dosing due to the critical nature of pulmonary infections.
Renal Impairment Adjustments
Flucloxacillin is primarily renally cleared, requiring dose reduction in renal dysfunction:
Creatinine Clearance (CrCl) based adjustments:
- CrCl >50 mL/min: No adjustment needed (100% of recommended dose)
- CrCl ≤50 mL/min (no dialysis): Reduce to 50% of recommended dose
- Regular hemodialysis: Give 100% of dose after each dialysis session
Practical application: For a patient on 12 g/day continuous infusion with CrCl 30 mL/min, reduce to 6 g/day continuous infusion. Monitor clinical response and consider therapeutic drug monitoring if available.
Important Caveats
Protein binding considerations: Flucloxacillin is 95-97% protein bound. In critically ill patients with hypoalbuminemia, the volume of distribution increases 2-fold compared to healthy volunteers 2. While total drug concentrations may appear adequate, unbound (active) concentrations may be subtherapeutic. This emphasizes the importance of using higher doses in critically ill patients.
Alternative for MSSA pneumonia: While the question specifically asks about flucloxacillin, note that the 2016 IDSA/ATS HAP/VAP guidelines recommend oxacillin, nafcillin, or cefazolin as preferred agents for proven MSSA 4. These agents are not typically used empirically but are preferred once MSSA is confirmed. Recent evidence suggests cefazolin may have comparable efficacy with less nephrotoxicity 5.
Duration and monitoring: For severe MSSA pneumonia, treatment duration typically extends 2-3 weeks minimum, with longer courses for complicated infections. Monitor renal function closely, particularly when using high doses or in patients with baseline renal impairment. Therapeutic drug monitoring of unbound concentrations, when available, can guide dosing in critically ill patients 2.
Continuous infusion logistics: Continuous infusion requires stable IV access and is particularly suitable for home-based parenteral therapy, where it has proven feasible and effective 1. Ensure flucloxacillin stability in solution over 24 hours and use appropriate diluents.